Biotech ‘pH Pharma’ led by alumni from Genentech and Hanmi

 To be a global healthcare company based both in Korea and U.S. through a shortening period of new drug development is pH Pharma’s goal. Hitnews went through pH Pharma from the date of foundation to the current.(For more information, please refer to the link below)

pH Pharma getting attention for its ‘license out’ during Pre-IPO

PH Pharma, which develops a treatment for glaucoma and non-alcoholic steatohepatitis (NASH), is conducting a pre-IPO (attracting funds before listing) worth 15 billion won. It is a form of large-scale purchase of new stocks (including preferred stocks) by domestic securities companies and management companies. The final goal is to be...